POLICY FOR COLLECTION AND TRANSFUSION OF GRANULOCYTES

REASON FOR ISSUE: Updated donor requirements, and starch product, included paediatric dose.

INTRODUCTION
Granulocyte transfusions as a means of treating patients with severe neutropenia and infections have been in clinical practice since the 1970s. However, it was not until research provided guidelines on the minimum number of granulocytes needed and until methods for achieving that number were available, that granulocyte transfusions became a viable therapeutic modality.

SCOPE
NZBS Collection Centres that provide therapeutic apheresis services to District Health Boards.

INDICATIONS
1. Therapeutic Granulocyte Transfusions
The literature has shown granulocyte transfusions may be beneficial and even life-saving in severely neutropenic patients with systemic bacterial or invasive fungal infections. The following criteria will be used in deciding whether to collect granulocytes:

- Persistent neutropenia with a neutrophil count < 0.2 x 10^9/l and likely to remain neutropenic for more than 5 days
- The disorder underlying the neutropenia (eg aplastic anaemia) has a good long-term prognosis in this patient
- A suitable donor is available from whom it is anticipated that a granulocyte collection of > 1.0 x 10^10 or, in the case of a paediatric patient, > 2 x 10^9/kg granulocytes is attainable

and either
- Septicaemia or life-threatening local infection not responding to 72 hours of appropriate antibiotics with significant risk of mortality or permanent morbidity
- Proven or probable invasive fungal or yeast infection refractory to appropriate anti-fungal therapy.

2. Prophylactic Granulocyte Transfusions
The limited literature available on prophylactic granulocyte transfusions does offer some support for high-dose cross-match compatible granulocyte transfusions. It is noted that Council of Europe does not currently include prophylaxis as an indication for granulocyte transfusions. Accordingly, all requests for prophylactic granulocyte transfusion will require discussion between NZBS and the clinician involved before commencing collection. The following criteria are the minimum requirements:

- Persistent neutropenia with a neutrophil count < 0.2 x 10^9/l, likely to remain neutropenic for more than 5 days
- The disorder underlying the neutropenia (eg aplastic anaemia) has a good long-term prognosis in this patient
- A suitable donor is available from whom it is anticipated that a granulocyte collection of > 1.0 x 10^10 or, in the case of a paediatric patient, > 2 x 10^9/kg granulocytes is attainable
And

- The patient is at high-risk of developing a serious bacterial or fungal infection.

CONTRA-INDICATIONS

Granulocyte transfusions will be considered to be contra-indicated if:
- The patient’s underlying disorder has a poor long-term prognosis
- The patient is being ventilated or has a severe respiratory abnormality
- Alloimmunisation to HLA antigens is known to be present

DONORS

Donors will be obtained from the patient’s family, from NZBS’s donors and from the New Zealand Bone Marrow Registry.
- The donors must meet the requirements of the current edition of the NZBS Collection Standards
- The donor must be ABO and Rh(D) compatible with the recipient.
- Where indicated and feasible, CMV negative and HLA compatible donors will be selected.
- If allogeneic stem cell transplantation is being considered, family members are relatively contra-indicated because of the risk of HLA alloimmunisation.
- The potential risk for thrombotic events should be considered when evaluating potential donors.
- An NZBS Medical Officer must evaluate all donors.
- Granulocytes are mobilized with either dexamethasone and/or G-CSF.

As part of the consent process, donors must be advised of the risks associated with the donation.
- Recognised side effects of dexamethasone include: headaches, insomnia, hunger, and euphoria. Very rarely, a single dose of steroids has been described as causing posterior subcapsular cataracts later in life
- Recognised side effects of G-CSF include bone pain, fatigue, and thrombotic complications secondary to thrombocytosis. Donors must also be advised of the theoretical leukaemogenicity risk.
- Recognised side effects of HES include: pruritis and, rarely, anaphylaxis. Coagulation disturbances and renal risks may be mentioned but are not considered real risks in view of the donor's healthy state and the small dose of HES administered.

MOBILISATION

A dose of 5-10 μg/kg of G-CSF subcutaneously and/or 8mg dexamethasone orally will be used to mobilise the granulocytes. G-CSF is the preferred option as granulocyte collections after G-CSF can be expected to significantly exceed the minimum of 1.0 \times 10^{10} per unit or 2 \times 10^8/kg for paediatric collections.

COLLECTION

Collection will take place under the supervision of an NZBS Medical Officer using a suitable apheresis collection machine. With the donor’s consent, a sedimenting agent comprising of Hydroxyethyl starch (HES), anticoagulated with trisodium citrate, will be used to enhance the collection.
TRANSFUSION

Granulocyte collections must not be leucodepleted, as this will remove the granulocytes. It is noted that the granulocyte collection will contain a large number of lymphocytes and that HLA alloimmunisation is a recognised complication of granulocyte transfusions. For the same reason all granulocyte collections must be irradiated prior to administration.

The granulocyte collection will be collected for and issued to a single named recipient. The collection should be transfused as soon as possible to the patient. If this is not possible, the granulocytes may be stored for up to 24 hours from the time of collection at 20 – 24 °C. The storage period must not exceed 24 hours. Do not agitate during storage.

Transport temperature of this component must be kept as close as possible to the recommended storage temperature and the system must be validated to ensure the transport temperature does not vary significantly from the recommended temperature.

The granulocytes must be transfused through a standard blood giving set with a 170-200μm filter. The administration of granulocytes and Amphotericin B infusion must be separated by several hours.

TECHNICAL SPECIFICATIONS

As per Granulocyte Apheresis Standards (112S022):